Pharmaceutical

Jazz’s cannabidiol therapy flunks in Japanese Phase III trial

Jazz’s cannabidiol oral solution, Epidiolex, is approved as an adjunct seizure treatment for three epileptic conditions in the US and Europe.

Aug 25, 2024 - 04:00
Jazz’s cannabidiol therapy flunks in Japanese Phase III trial
Jazz’s cannabidiol oral solution, Epidiolex, is approved as an adjunct seizure treatment for three epileptic conditions in the US and Europe.
Read the original article

Tags:

Previous Article

Eli Lilly doubles down on Oblique partnership for antibody generation

Next Article

A comprehensive guide to supply chain management for specialty drugs

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Helsinn and Angelini Pharma renew AULIN and MESULID distribution deal

Helsinn and Angelini Pharma renew AULIN and MESULID di...

May 29, 2024

STAT+: Generic group sues Minnesota over a drug pricing transparency law it calls an ‘unconstitutional overreach’

STAT+: Generic group sues Minnesota over a drug pricing...

Jul 6, 2023

STAT+: The FDA is testing new nutrition labels on the front of food packages

STAT+: The FDA is testing new nutrition labels on the f...

Jun 20, 2023